According to the Guideline, an MRI scan is recommended to search for intracranial lesions in cases of new-onset unprovoked seizure. Actually, seizure is a relatively common symptom in lesional cases, such as brain tumor. The possible comorbidity rate of epilepsy and tumor is reported to be 29-60% and 20-35% in meningiomas and metastatic tumors, respectively. And more than 80% of low grade glioma patients suffer from epilepsy, a rate that is even more frequent than in malignant cases (29-49%). Perhaps the tumors with the most well-known clinical pathology of all epileptic tumors are glioneural tumors. These tumors are believed to be epileptogenic by nature, and complete ablation of the epileptogenic area is necessary in any attempt to improve seizure control. On the other hand, the ILAE (International League Against Epilepsy) proposed a new classification for focal cortex dysplasia (FCD) in 2011. Under this classification FCD co-exists with and/or is close to the tumor (FCD Type IIIb). Such new clinical criteria were proposed, because subtle FCD undetectable with MRI could be epileptogenic in some tumor cases. Surgical success relies upon the complete resection of the epileptogenic areas and perfect protection of the functional areas at the same time. Pre-surgical evaluation, such as functional MRI and DTI (diffusion tensor imaging) trac- tography is required for safe surgery. And moreover, intraoperative mapping of the cortex with stimulating and recording electrodes is now widely employed in the resection of lesions involving or adjacent to the eloquent areas, especially with awake craniotomy. As for conservative therapy of epilepsy along with brain tumors, there are few prospective studies concerning the choice of antiepileptic drug. Finally, there is no clinical evidence for the prophylactic use of antiepileptic drugs for brain tumor cases without seizure.